-
New Hope for ALS: Cellenkos Receives FDA Fast Track Designation for CK0803
A Breakthrough for ALS Treatment The fight against Amyotrophic Lateral Sclerosis (ALS) has reached a significant milestone. Cellenkos, a clinical-stage biotechnology company, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to their investigational therapy, CK0803. What is CK0803? CK0803 is an innovative allogeneic cell therapy derived from umbilical…
-
Revolutionizing Neurodegenerative Care: New Study Validates At-Home Monitoring for ALS and FTD
A Breakthrough in Remote Cognitive Assessment Managing neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) has historically required frequent, burdensome trips to clinical sites. However, a recent study published in Scientific Reports reveals a promising shift in how we monitor these conditions. Cumulus Neuroscience has announced that its NeuLogiq platform has been…
-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
BrainStorm Cell Therapeutics | Announces FDA Advisory Committee Meeting to Review NurOwn® PDUFA Target Action Date Scheduled for December 8, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that the US FDA has granted the company a meeting to discuss the regulatory path forward for NurOwn® in ALS. The meeting, scheduled for December 6, 2023, will focus on plans for a Special Protocol Assessment (SPA) for a confirmatory Phase 3 trial in ALS. BrainStorm aims to…